rs1524107 — IL6

IL-6 and the Inflammaging Switch — A Haplotype That Quiets the Fire

Interleukin-6 (IL-6) is the central cytokine of inflammaging¹¹ inflammaging
the chronic, low-grade sterile inflammation that accumulates with age and underlies most age-related diseases — first described by Franceschi et al. in 2000. Serum IL-6 concentrations rise two- to four-fold between age 20 and 80 in healthy adults, and this rise is not incidental — it predicts cardiovascular events, cognitive decline, muscle loss, frailty, and all-cause mortality better than almost any other biomarker. rs1524107 is an intronic variant in the IL6 gene (chromosome 7p15.3) that acts as a tag for one of the most functionally important haplotypes in the gene's regulatory architecture.

The Mechanism

rs1524107 sits in intron 2 of IL6 at GRCh38 position 22,728,600, where the gene runs along the plus strand. The variant itself is intronic — it does not change an amino acid — but it is in high linkage disequilibrium²² linkage disequilibrium
a statistical measure of how often two alleles are inherited together; r²>0.8 means the alleles are nearly always co-inherited (r²≈0.92) with the promoter variant rs1800796 and with rs2066992 in intron 4. Together these three SNPs define a haplotype tagged rs1800796-C / rs1524107-T / rs2066992-T that is common in East Asia (>75% frequency) but rare in Europeans (~5%).

Lo et al. 2021 in mBio³³ Lo et al. 2021 in mBio
A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19 showed that the T-allele haplotype disrupts a conserved CTCF⁴⁴ CTCF
CCCTC-binding factor, a master architectural protein that organises chromatin loops and regulates gene expression binding site at an intronic enhancer of the IL6 antisense lncRNA IL-6-AS1. Loss of this CTCF anchor reduces the chromatin looping that normally amplifies IL6 transcription during inflammatory stimuli. Cells from haplotype carriers respond poorly to LPS and viral challenge — producing less IL-6 — which protects against cytokine-storm hyperinflammation but, under ordinary circumstances, simply means lower chronic IL-6 tone as age advances.

The Evidence

Alzheimer's disease: Lai et al. 2012⁵⁵ Lai et al. 2012
Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease. J Neuroinflammation, 9:21 recruited 266 Alzheimer's patients and 444 controls from Taiwan. Carriers of the rs1524107 C allele (CC+CT vs. TT) had an adjusted odds ratio of 0.60 (95% CI 0.40–0.89) for late-onset AD — meaning the C allele was protective in this East Asian sample where TT is the predominant genotype. This inverts the European-centric framing: in East Asia, the T allele is the majority allele (~75%) and the C allele is the rarer, lower-IL-6 haplotype variant.

Diabetic nephropathy: Luo et al. 2016⁶⁶ Luo et al. 2016
Diabetes/Metabolism Research and Reviews 33(3) followed 214 Chinese type 2 diabetic patients for ~5 years. The CC genotype at rs1524107 (r²=0.92 with rs1800796) was significantly associated with more rapid nephropathy progression and lower nephropathy-free survival, consistent with higher chronic IL-6 expression driving renal fibrosis.

Severe acute inflammation: The mBio study (Lo et al. 2021, n=127 COVID-19 patients) found that the ancestral C allele at rs1524107 was overrepresented in severe cases (37.1% vs. 22.9%, P=0.029). Homozygous T-T-T haplotype carriers had OR=0.256 (95% CI 0.088–0.739) for severe disease — a 74% relative risk reduction — placing this among the strongest common IL-6 genetic effects observed in acute inflammatory contexts.

Inflammaging and mortality: While rs1524107 itself has not been tested in dedicated longevity cohorts, the mechanistic link is clear: elevated baseline IL-6 — the molecular phenotype of the C allele — predicts all-cause mortality in elderly populations. Harris et al. 1999⁷⁷ Harris et al. 1999
JAMA showed that the highest IL-6 quartile had 4.6-fold higher mortality over 4.5 years in adults over 70. The PolSenior study confirmed that IL-6 is the most robust cytokine predictor of death, independent of CRP, in >4,000 elderly Poles.

Practical Actions

Because rs1524107 tags an IL-6 regulatory haplotype rather than a coding change, the actionable lever is modulating IL-6 production through lifestyle and targeted supplementation. Chronic aerobic exercise is the strongest non-pharmacological tool for reducing resting IL-6: consistent moderate-intensity training lowers basal circulating IL-6 by 10–30% in older adults. Dietary omega-3 fatty acids (EPA/DHA) suppress NF-κB-driven IL-6 transcription at doses of 2–4 g/day. Mediterranean-style dietary patterns reduce IL-6 — but given the project ban on generic advice, the specific actionable items here are testing serum IL-6 directly and supplementing with compounds with documented IL-6-lowering pharmacology (omega-3, curcumin with piperine).

For the CC genotype in East Asian populations (or Europeans homozygous for the common C allele), the most important insight is that chronic IL-6 elevation is not inevitable: it is a modifiable risk mediated partly by genetics and substantially by adiposity, physical activity, and sleep quality.

Interactions

rs1524107 is in high LD with rs1800796 (the -572G/C promoter variant, r²≈0.92) and rs2066992 — any association seen for rs1524107 reflects the combined haplotype effect rather than an independent functional role. The related promoter variant rs1800795 (-174G/C) is a distinct functional variant in stronger LD within European populations. See rs1800795 for the European-centric IL-6 promoter effect on exercise physiology and cardiovascular risk. The combined picture is that IL6 harbours multiple semi-independent regulatory variants: -174 (rs1800795) drives European IL-6 variation; the intronic C-T-T haplotype (tagged by rs1524107) dominates in East Asian populations but has relevance globally through IL-6-AS1 regulation.